JP2019526632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526632A5 JP2019526632A5 JP2019531873A JP2019531873A JP2019526632A5 JP 2019526632 A5 JP2019526632 A5 JP 2019526632A5 JP 2019531873 A JP2019531873 A JP 2019531873A JP 2019531873 A JP2019531873 A JP 2019531873A JP 2019526632 A5 JP2019526632 A5 JP 2019526632A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- cancer
- hydrate
- pharmaceutically acceptable
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 15
- 239000003246 corticosteroid Substances 0.000 claims description 12
- 238000012423 maintenance Methods 0.000 claims description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 5
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 241000321096 Adenoides Species 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims 2
- 201000005171 Cystadenoma Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 210000002534 adenoid Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 2
- 229960003290 cortisone acetate Drugs 0.000 claims 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims 2
- 230000000762 glandular Effects 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims 2
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229950010765 pivalate Drugs 0.000 claims 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- -1 cortisone steroid Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022209634A JP2023052108A (ja) | 2016-08-31 | 2022-12-27 | 固形腫瘍の治療のための投薬レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381911P | 2016-08-31 | 2016-08-31 | |
| US62/381,911 | 2016-08-31 | ||
| PCT/US2017/048308 WO2018044662A1 (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209634A Division JP2023052108A (ja) | 2016-08-31 | 2022-12-27 | 固形腫瘍の治療のための投薬レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526632A JP2019526632A (ja) | 2019-09-19 |
| JP2019526632A5 true JP2019526632A5 (enExample) | 2020-10-01 |
Family
ID=59772787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531873A Pending JP2019526632A (ja) | 2016-08-31 | 2017-08-24 | 固形腫瘍の治療のための投薬レジメン |
| JP2022209634A Pending JP2023052108A (ja) | 2016-08-31 | 2022-12-27 | 固形腫瘍の治療のための投薬レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209634A Pending JP2023052108A (ja) | 2016-08-31 | 2022-12-27 | 固形腫瘍の治療のための投薬レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190209581A1 (enExample) |
| EP (1) | EP3506905B1 (enExample) |
| JP (2) | JP2019526632A (enExample) |
| KR (1) | KR102512899B1 (enExample) |
| CN (2) | CN109562114A (enExample) |
| AU (1) | AU2017321011B2 (enExample) |
| BR (1) | BR112019002461A2 (enExample) |
| CA (1) | CA3035616A1 (enExample) |
| ES (1) | ES2977556T3 (enExample) |
| IL (2) | IL305136A (enExample) |
| MA (1) | MA46086A (enExample) |
| MX (1) | MX387397B (enExample) |
| SG (2) | SG10202107832UA (enExample) |
| WO (1) | WO2018044662A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| RU2754452C2 (ru) | 2016-04-12 | 2021-09-02 | Эли Лилли Энд Компани | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака |
| ES2881801T3 (es) | 2016-04-12 | 2021-11-30 | Lilly Co Eli | Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón |
| KR102463617B1 (ko) | 2016-05-20 | 2022-11-03 | 일라이 릴리 앤드 캄파니 | Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| SG11201907580SA (en) | 2017-02-17 | 2019-09-27 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US46206A (en) | 1865-02-07 | Improved vessel for holding petroleum | ||
| WO2008112249A1 (en) * | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| KR101245604B1 (ko) * | 2007-11-13 | 2013-03-21 | 메리테이지 파마, 인크. | 코르티코스테로이드 조성물 |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| KR20170029490A (ko) * | 2014-07-11 | 2017-03-15 | 제넨테크, 인크. | 노치 경로 억제 |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
-
2017
- 2017-08-24 SG SG10202107832UA patent/SG10202107832UA/en unknown
- 2017-08-24 CA CA3035616A patent/CA3035616A1/en active Pending
- 2017-08-24 WO PCT/US2017/048308 patent/WO2018044662A1/en not_active Ceased
- 2017-08-24 KR KR1020197005847A patent/KR102512899B1/ko active Active
- 2017-08-24 IL IL305136A patent/IL305136A/en unknown
- 2017-08-24 MX MX2019002066A patent/MX387397B/es unknown
- 2017-08-24 SG SG11201901325UA patent/SG11201901325UA/en unknown
- 2017-08-24 IL IL264924A patent/IL264924B2/en unknown
- 2017-08-24 AU AU2017321011A patent/AU2017321011B2/en active Active
- 2017-08-24 MA MA046086A patent/MA46086A/fr unknown
- 2017-08-24 US US16/328,267 patent/US20190209581A1/en not_active Abandoned
- 2017-08-24 CN CN201780052146.2A patent/CN109562114A/zh active Pending
- 2017-08-24 ES ES17761723T patent/ES2977556T3/es active Active
- 2017-08-24 CN CN202310314953.4A patent/CN116473978A/zh active Pending
- 2017-08-24 BR BR112019002461A patent/BR112019002461A2/pt not_active Application Discontinuation
- 2017-08-24 EP EP17761723.0A patent/EP3506905B1/en active Active
- 2017-08-24 JP JP2019531873A patent/JP2019526632A/ja active Pending
-
2022
- 2022-12-27 JP JP2022209634A patent/JP2023052108A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526632A5 (enExample) | ||
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| JP2018109022A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2020516646A5 (enExample) | ||
| CN110996927A (zh) | 复发性胶质母细胞瘤(rgbm)的治疗方法 | |
| BR112020024062A2 (pt) | métodos para o tratamento de tumores de restos adrenais de testículo e de ovário | |
| JP2019529581A5 (enExample) | ||
| TW202120096A (zh) | 使用包含atp競爭性akt抑制劑、cdk4/6抑制劑及氟維司群之組合療法治療乳癌 | |
| JP2019515889A (ja) | （１ｓ，４ｓ）−４−（２−（（（３ｓ，４ｒ）−３−フルオロテトラヒドロ−２ｈ−ピラン−４−イル）アミノ）−８−（（２，４，６−トリクロロフェニル）アミノ）−９ｈ−プリン−９−イル）−１−メチルクロロヘキサン−１−カルボキサミドの固体形態及びその使用方法 | |
| JP7376540B2 (ja) | リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体２陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ | |
| IL259512B2 (en) | Combination for the effective treatment of metastatic cancer in patients | |
| Abramson et al. | Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up | |
| O'Neil et al. | A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer | |
| EP3352734B1 (en) | Treatment of alopecia areata | |
| TWI719765B (zh) | 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療 | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP7541512B2 (ja) | プロドラッグおよびその医学的使用 | |
| WO2019174590A1 (zh) | 用于治疗三阴性乳腺癌的喹啉衍生物 | |
| JP6359197B2 (ja) | がんの組合せ療法 | |
| Ceresoli et al. | Pleural mesothelioma: long-term progression-free survival with Tumor Treating Fields (TTFields) therapy case reports | |
| JP2016521760A5 (enExample) | ||
| JP2015520763A5 (enExample) | ||
| Tatekawa et al. | COVID-19 vaccine-induced Recurrence of the Radiation Recall Phenomenon in the Laryngeal Mucosa Due to a VEGF Inhibitor | |
| JPWO2020097625A5 (enExample) |